Welcome to our newsroom.
401 North Washington St.
Suite 700
Rockville, MD 20850
Brian Hochheimer,
Chief Financial Officer
Send Mail
The Emmes Corporation today announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “The win is important because it expands our role in combating the Zika virus, a significant and enduring public health challenge.”
The Emmes Corporation today announced the highest revenues in its 40‐year history along with significant growth in its employee count. Revenues surpassed $90 million in 2016, and it employed 567 employees in its U.S. and international offices.
The Emmes Corporation today announced that a large team of scientists and health professionals including those from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have authored a series of papers summarizing significant research on traumatic brain injury in the military.
The Emmes Corporation today announced that it was selected as one of the best places to work in the greater Washington area. In its third annual survey, The Washington Post’s Top Workplaces list spotlighted private, public, nonprofit and government agencies with the highest engagement ratings from their employees in a survey conducted by Workplace Dynamics. There were 150 organizations selected for the Top Workplaces award, and Emmes was recognized as a top mid-size company and one of only three biotechnology organizations making the list.
The Emmes Corporation today announced that it contributed to a landmark research study by the National Institutes of Health linking air pollution and preterm birth risk in pregnant women with asthma. The study, published in the Journal of Allergy and Clinical Immunology, reported that pregnant women with asthma have an increased risk for preterm birth when exposed to high levels of nitrogen oxides and carbon monoxide, common traffic-related air pollutants.
The Emmes Corporation today announced that Dr. Paul VanVeldhuisen has been promoted to the newly created position of chief operating officer. Dr. VanVeldhuisen, who started at Emmes as a statistician and epidemiologist, will assume the additional leadership responsibilities while continuing to serve as principal investigator for government and privately funded research projects.
One Emmes employee received special recognition by the National Institutes of Health (NIH) for her team’s support in responding to the Ebola outbreak. Phyllis Renehan, an Emmes project director, was the only non-government member of the Ebola vaccine team that received the award given during the National Institute of Allergy and Infectious Diseases’ annual awards ceremony on November 2, 2015.
The Emmes Corporation today announced that three of its statisticians, Dr. Ravinder Anand, Dr. Traci Clemons and Karen Martz, co-authored a pivotal study that examined lithium as a treatment for pediatric bipolar I disorder. The study was published in the October issue of Pediatrics.
The Emmes Corporation today announced that one of its principal investigators and statisticians, Dr. Traci Clemons, co-authored a study that was just published by the Journal of the American Medical Association (JAMA).
The New "Mercy TAPE" Estimates Pediatric Weight with Greater Accuracy, Giving Doctors a Better Tool for Determining Prescription Dosage.